On February 4, the Chongqing Securities Regulatory Bureau announced that Chongqing Shanwaishan Blood Purification Technology Co., Ltd. (hereinafter referred to as "Shanwaishan") has signed a counseling agreement with the sponsoring institution to publicly issue shares and list them.
According to the reporter's understanding, Shanwaishan is one of the first batch of key training enterprises to be listed in Chongqing in 2017. In October 2018, based on strategic considerations for the capital market, the company terminated its listing on the New Third Board. In 2020, as a leading enterprise and standard drafting unit in China's blood purification industry, Shanwaishan completed a strategic financing of hundreds of millions of yuan, which was led by Hillhouse Venture Capital.
Shanwaishan Company has become a company in the whole industrial chain of blood purification
Hillhouse Venture Capital led the investment
Shanwaishan completed hundreds of millions of yuan of strategic financing
According to the data of Tianyancha, Chongqing Shanwaishan Blood Purification Technology Co., Ltd. was established on March 26, 2001, with a registered capital of 108.54026 million yuan, and its registered address is No. 1, Tzu Chi Road, Liangjiang New District, Yubei District, Chongqing, and the actual controller is Gao Guangyong. The company's main business is the research and development, production and sales of blood purification equipment, the operation of hemodialysis consumables and the construction of hemodialysis center. On August 1, 2016, Shanwaishan was listed on the national small and medium-sized enterprise share transfer system and delisted in October 2018. As for the reason for the delisting, Shanwaishan once said that in order to promote the company's better development, it is based on strategic considerations for the capital market.
It is understood that as a leading enterprise in the hemodialysis industry, Shanwaishan has participated in the drafting and formulation of 2 national standards and 5 industry standards in the field of blood purification in China, and is a national innovative enterprise and a national technological innovation demonstration enterprise. In October 2020, Shanwaishan announced the completion of a strategic financing of hundreds of millions of yuan. This round of financing is led by Hillhouse Venture Capital, followed by Xiangjiang Industry and Xiangjiang Liyuan Jianhuan.
Build a whole industry chain company
The annual output value of the "dialysate" plant may exceed 600 million
As a whole industry chain company integrating blood purification equipment, blood purification consumables, blood purification intelligent management system and chain hemodialysis center, Shanwaishan has been deeply cultivating the field of blood purification for more than 20 years, and the blood purification equipment is exported to the domestic and foreign markets, the main customers are major medical institutions at home and abroad, the customers include Beijing 301 Hospital, Nanjing Military Region General Hospital, Xiangya Second Hospital, Army Military Medical University Xinqiao Hospital and many other well-known domestic large-scale tertiary hospitals, and exported to Indonesia, the Philippines, South Africa and other countries and regions.
According to the last revenue data released by Shanwaishan on the New Third Board, the revenue in the first half of 2018 was 53.89 million yuan, an increase of 57.02% year-on-year, and the operating cost was 3512 million yuan, an increase of 77.87% year-on-year. Net profit attributable to listed companies - 5.89 million yuan, a decrease of 97.18% year-on-year. The increase in operating income and operating costs was mainly due to the company's expansion of sales during the reporting period and the significant increase in sales of machines and consumables. In 2019, Shanwaishan Company began to exert force in the hemodialysis consumables section of one of the three major plates, and its wholly-owned subsidiary Tianwaitian Company is committed to the research and development and production of hemodialysis consumables, including dialysate, dialysis powder, dialyzers and other series of hemodialysis consumables, and a modern "dialysate" production plant, which will be put into production in 2019, and the annual output value is expected to exceed 600 million.
Newsmakers
Founder Gao Guangyong was originally an engineer
Start a business in a 60㎡ residential building
Gao Guangyong, founder and actual controller of Chongqing Shanwaishan
The prosperity and progress of an industry is inseparable from the innovative leadership of a group of outstanding enterprises and the pioneering spirit of a group of leading figures. The development and growth of Chongqing's shanwaishan is also inseparable from the efforts of the founder and actual controller Gao Guangyong.
Gao Guangyong, male, born in December 1969, master's degree. From June 1995 to October 1997, Gao Guangyong served as an engineer in the technical department of Qingling Motors Co., Ltd., and from November 1997 to March 2001, Gao Guangyong served as a sales manager in the sales department of Chongqing Rainwater Enterprise (Group) Co., Ltd. In March 2001, Gao Guangyong started from scratch and founded Chongqing Shanwaishan Technology Co., Ltd., the predecessor of Chongqing Shanwaishan Blood Purification Technology Co., Ltd., in a residential building of more than 60 square meters.
Gao Guangyong, chairman of Shanwaishan, said that unlike drug innovation, medical device product iteration is faster, and only by adhering to innovative research and development can we ensure that the update frequency of products is not eliminated by the market. For a long time, the domestic high-end medical device market has been occupied by imported brands, especially in the field of blood purification equipment. After carrying through the shortage of funds, the shortage of talents, research and development failures and other difficulties, Gao Guangyong led the team to innovate and develop independently, conquered a series of core key technologies of blood purification equipment, successfully developed China's first continuous blood purification system and the first online hemodialysis filter, filling the gap of China's high-end blood purification equipment. In 2017, he was selected into the list of the National Innovative Talent Promotion Plan of the Ministry of Science and Technology, and in 2019, he was awarded the "Top Ten Chongqing Economic Innovators of the Year".
Upstream News Chongqing Business Daily reporter Feng Shengyong
Source: Upstream News Bring together the upward forces